Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sanjay Shankar

Interventional Cardiology Phoenix, AZ Medical Doctor

NPI 1881893121 CMS profile 221981

9520 W Palm Ln Ste 150, Phoenix, AZ 85037

Open in the dashboard

General payments

$11,898

354 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sanjay Shankar of Phoenix, AZ is reported in the CMS Open Payments database as having received $11,898 across 354 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,690 43
2024 General $2,030 54
2023 General $2,028 62
2022 General $2,377 60
2021 General $1,566 61
2020 General $1,376 57
2019 General $831 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sanjay Shankar
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Sanjay Shankar were reported at $1,690. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Sanjay Shankar Interventional Cardiology median Middle half National median
2019 $831 $1,097 $329–$3,048 $163
2020 $1,376 $473 $161–$1,480 $114
2021 $1,566 $677 $233–$1,827 $132
2022 $2,377 $978 $333–$2,724 $149
2023 $2,028 $1,136 $382–$2,986 $160
2024 $2,030 $1,181 $395–$3,326 $164
2025 $1,690 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $3,473 61 payments
  2. Abiomed $1,193 17 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $769 26 payments
  4. Medtronic, Inc. $746 8 payments
  5. Boston Scientific Corporation $690 18 payments
  6. Novartis Pharmaceuticals Corporation $687 37 payments
  7. Merck Sharp & Dohme Corporation $580 27 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $482 20 payments
  9. Janssen Pharmaceuticals, Inc $302 19 payments
  10. Pfizer Inc. $248 14 payments
  11. Other $2,728 107 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,845 346 payments
  2. Travel and Lodging $796 4 payments
  3. Education $256 4 payments
Products named General payments · program years 2019–2025
  1. Impella $912 13 payments
  2. Fortify Assura $815 5 payments
  3. LifeVest $769 26 payments
  4. VERQUVO $759 34 payments
  5. Mitra Clip system $398 5 payments
  6. JARDIANCE $377 15 payments
  7. LEQVIO $361 19 payments
  8. CardioMEMS HF System $354 3 payments
  9. COREVALVE EVOLUT R $352 4 payments
  10. GALLANT $319 5 payments
  11. Other $7,096 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,712

Median for Interventional Cardiology: 2,236

Drug cost

$605,078

Median for Interventional Cardiology: $380,412

Branded share of claims

26.3%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 183 $245,353
Entresto Sacubitril/Valsartan Brand 83 $108,716
Jardiance Empagliflozin Brand 91 $96,405
Xarelto Rivaroxaban Brand 70 $77,833
Farxiga Dapagliflozin Propanediol Brand 30 $32,523
Repatha Sureclick Evolocumab Brand 14 $9,825
Brilinta Ticagrelor Brand 11 $9,729
Metoprolol Succinate Generic 396 $4,453
Atorvastatin Calcium Generic 279 $3,034
Ranolazine Er Ranolazine Brand 13 $2,202

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 88 billing codes

Paid by Medicare

$338,032

Of which drugs: $1,086

Medicare patients

758

Average age 76

Services billed

5,232

392 women, 366 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Ischemic heart disease 54%
Chronic kidney disease 46%
Diabetes 43%
Heart failure 42%
Atrial fibrillation 41%
COPD 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 40 154 $795
Injection, fentanyl citrate, 0.1 mg J3010 Office 15 236 $163
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 17 1,112 $115
Injection, midazolam hydrochloride, per 1 mg J2250 Office 16 19 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $179
$179 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $83
$83 91 —
Repatha
  • Amgen Inc. $48
$48 14 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $42
$42 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $42
$42 83 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

354 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record